Flavia Borellini
Net worth: 5 M $ as of 2026-06-29
Net worth: 5 M $ as of 2026-06-29
Flavia Borellini is currently an Independent Director at Cantargia AB since 2020, an Independent Director at Revolution Medicines, Inc. since 2021, a Director at Kartos Therapeutics, Inc. since 2018, and an Independent Director at Pliant Therapeutics, Inc. starting in 2026.
Former roles include Chief Executive Officer at Acerta Pharma BV from 2016 to 2019, Independent Director at Viracta Therapeutics, Inc. from 2021 to 2025, VP-Global Product & Portfolio Strategy at AstraZeneca PLC from 2018 to 2020, Vice President-Program Leadership at Onyx Pharmaceuticals, Inc. from 2012 to 2013, and Member at Roche Group.
Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-17 | 26,215 ( 0.01% ) | 5 M $ | 2026-06-29 | |
| 2026-07-08 | 0 ( -.--% ) | - $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Director/Board Member | 2021-06-21 |
| CANTARGIA AB | Director/Board Member | 2020-09-30 |
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 2026-07-08 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Director/Board Member | 2018-01-31 |
| Companies | Position | End |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 2025-02-04 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 2019-12-31 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Chief Executive Officer | 2019-01-31 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 2013-09-30 |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Health Technology |
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
Select your edition
All financial news and data tailored to specific country editions